logo
DYAI_virus
Mono and Multi-Valent RBD-based Blended Vaccine – Based on the RBD antigen cell lines that we have constructed to express Wuhan, Alpha, Beta, Gamma, Delta, and Omicron BA.1 and BA.5 CoV-2 variants, additional animal data is being generated through several preclinical trials using mono and multi-valent blends of C1 produced SARS-CoV-2 RBD variants of concern

Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced its financial results for the third quarter of 2022, and highlighted recent company developments

By Dyadic International, Inc.
Published - Nov 10, 2022, 04:05 PM ET
Last Updated - Mar 22, 2024, 01:57 PM EDT
  • Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrateclinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidate
  • Presentedsafety,efficacy,andproductivitydataatWorldVaccineCongressEurope
  • Newandexpandedcollaborationswithtopanimalhealthcompaniestodevelopvaccinesandtreatmentsforcompanionandlivestockanimaldiseases
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024